Pharmaceutical Executive

DTC pharma advertising is under pressure from multiple directions: tightening regulations under the Trump Administration, eroding consumer trust, and the rise of precision digital targeting. And, the industry is being forced to rethink its playbook. In this Pharmaceutical Executive video interview, Impiricus co-founder Sandy Donaldson lays out where DTC is headed and what it means for how pharma reaches both consumers and physicians. Responsory’s takeaway: The era of mass DTC TV is giving way to something more targeted, more digital, and more physician-centric. Smart marketers won’t just adapt to the regulatory constraints — they’ll get ahead of the shift by doubling down on HCP education, disease awareness campaigns, and precision digital engagement that builds trust rather than backlash.

View article >

In this Q&A, pharmaceutical executive, Katrina Rice, discusses how the industry is navigating a shift in Diversity, Equity, and Inclusion (DE&I) strategies following administrative and regulatory changes. Rather than treating DE&I as a standalone initiative, companies are increasingly embedding these principles into core business operations, particularly within clinical trial recruitment and community partnerships to ensure long-term health equity. Moving into 2026, the industry is expected to rely more heavily on data analytics to measure the success of fair representation in both research and leadership. Responsory’s takeaway: This operational shift isn’t just ethical; it’s a competitive advantage. Companies that integrate equity into their business strategy will differentiate themselves through stronger innovation, patient trust, and market resilience in an uncertain regulatory landscape.

View article